Results 81 to 90 of about 77,108 (288)

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Single‐Cell Dissection of Tumor‐Infiltrating Lymphocytes Reveals Cellular Architecture Predictive of Therapeutic Efficacy in Acral Melanoma

Advanced Science, EarlyView.
Autologous tumor‐infiltrating lymphocyte (TIL) therapy shows promising efficacy in acral melanoma, yet determinants of durable response remain unclear. By integrating single‐cell transcriptomics and TCR sequencing, this study reveals that TIL products enriched for T follicular helper and intermediate exhausted T cells establish persistent clonal ...
Chao Zhang, Wanyi Xiao, Hongru Shen, Fenge Li, Ting Li, Weihong Zhang, Haotian Liu, Ziwei Gao, Hongyu Wang, Xiubao Ren, Kexin Chen, Xiangchun Li, Jilong Yang   +12 more
wiley   +1 more source

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Journal of Translational Medicine, 2012
Background Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clinical benefit and toxicity of ...
Wang Wenshi, Yu Daohai, Sarnaik Amod A, Yu Bin, Hall Maclean, Morelli Dawn, Zhang Yonghong, Zhao Xiuhua, Weber Jeffrey S   +8 more
doaj   +1 more source

Biological therapy in the treatment of melanoma [PDF]

, 2018
Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile, Georgescu, Simona Roxana, Ghita, Ela, Ioghen, Mihaela Roxana, Ion, Alexandra-Florentina, Mitran, Cristina-Iulia, Mitran, Madalina-Irina, Sarbu, Maria Isabela, Tampa, Mircea   +8 more
core   +3 more sources

Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT The therapeutic landscape of hepatocellular carcinoma (HCC) has been transformed by recent advancements in systemic therapies, particularly with the introduction of immune checkpoint inhibitors, expanding treatment options beyond conventional locoregional approaches.
Keiichi Akahoshi, Shun Kaneko, Shinji Tanaka, Minoru Tanabe, Daisuke Ban   +4 more
wiley   +1 more source

Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. [PDF]

, 2020
BackgroundCTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire.
Cham, Jason, Fong, Grant, Fong, Lawrence, He, Tao, Kwek, Serena, Oh, David Y, Paciorek, Alan, Zhang, Li   +7 more
core   +1 more source

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Journal of Clinical Oncology, 2021
PURPOSE In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability.
T. Owonikoko, Keunchil Park, R. Govindan, N. Ready, M. Reck, S. Peters, S. Dakhil, A. Navarro, J. Rodríguez-Cid, M. Schenker, Jong-Seok Lee, V. Gutiérrez, I. Percent, D. Morgensztern, C. Barrios, L. Greillier, S. Baka, Miten R. Patel, Wen-hong Lin, G. Selvaggi, C. Baudelet, J. Baden, D. Pandya, P. Doshi, H. R. Kim   +24 more
semanticscholar   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello, Mazzone, Roberta, Valente, Sergio, Zwergel, Clemens   +3 more
core   +1 more source

Harnessing nanomaterials to precisely regulate the immunosuppressive tumor microenvironment for enhanced immunotherapy

BMEMat, EarlyView.
The immunosuppressive tumor microenvironment, characterized by hypoxia, redox imbalance, elevated interstitial fluid pressure, and acidity, was comprehensively elucidated. This review discussed the etiology and consequences of the characteristics of the immunosuppressive tumor microenvironment, and analyzed the recent advancements in nanomaterials for ...
Wen Zhang, Xueyin Hu, Wei Cheng, Lumeng Zhang, Yuanfang Chen, Qinrui Fu, Luntao Liu, Saijun Fan   +7 more
wiley   +1 more source